• AMA-101: An example of a small molecule drug against Parkinson’s disease.

• Preclinical data demonstrating the AMA-101’s mechanism of action.

• The unique set of metabolites that are produced by a healthy gut microbiota and the maintenance of health and their mechanistic importance in Parkinson’s disease.

• Utilising Amabiotic’s microbiome indication screening process for small molecule drug discovery.

• How microbiome-derived diagnostics can pave the way for personalized medicines to treat gut-brain  disorders such as Parkinson’s.